Alkermes Plc (ALKS)
46.02
-0.16
(-0.35%)
USD |
NASDAQ |
Nov 20, 12:00
Alkermes Cash from Operations (Quarterly) : 93.48M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 93.48M |
| June 30, 2026 | 145.18M |
| March 31, 2026 | -165.74M |
| December 31, 2025 | 170.07M |
| September 30, 2025 | 101.67M |
| June 30, 2025 | 150.20M |
| March 31, 2025 | 98.81M |
| December 31, 2024 | 190.40M |
| September 30, 2024 | 81.59M |
| June 30, 2024 | 146.03M |
| March 31, 2024 | 21.11M |
| December 31, 2023 | 107.24M |
| September 30, 2023 | 99.71M |
| June 30, 2023 | 215.71M |
| March 31, 2023 | -21.30M |
| December 31, 2022 | 1.047M |
| September 30, 2022 | 0.625M |
| June 30, 2022 | -2.306M |
| March 31, 2022 | 21.68M |
| December 31, 2021 | 31.02M |
| September 30, 2021 | 82.78M |
| June 30, 2021 | 33.06M |
| March 31, 2021 | -45.15M |
| December 31, 2020 | 67.34M |
| September 30, 2020 | 60.20M |
| Date | Value |
|---|---|
| June 30, 2020 | -4.432M |
| March 31, 2020 | -40.27M |
| December 31, 2019 | 42.07M |
| September 30, 2019 | 30.97M |
| June 30, 2019 | -23.18M |
| March 31, 2019 | 22.21M |
| December 31, 2018 | 60.51M |
| September 30, 2018 | 33.48M |
| June 30, 2018 | 32.13M |
| March 31, 2018 | -26.84M |
| December 31, 2017 | 35.91M |
| September 30, 2017 | 19.48M |
| June 30, 2017 | -22.45M |
| March 31, 2017 | -13.75M |
| December 31, 2016 | 4.129M |
| September 30, 2016 | 14.73M |
| June 30, 2016 | -28.88M |
| March 31, 2016 | -57.21M |
| December 31, 2015 | 2.415M |
| September 30, 2015 | -29.45M |
| June 30, 2015 | -15.41M |
| March 31, 2015 | 2.077M |
| December 31, 2014 | 13.64M |
| September 30, 2014 | -7.809M |
| June 30, 2014 | 8.777M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Amarin Corp. Plc | 9.218M |
| Prothena Corp. Plc | -11.88M |
| Cue Biopharma, Inc. | -10.08M |
| ACADIA Pharmaceuticals, Inc. | 11.50M |
| Alnylam Pharmaceuticals, Inc. | 340.98M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 19.99M |
| Cash from Financing (Quarterly) | 6.318M |
| Free Cash Flow | 227.37M |
| Free Cash Flow Per Share (Quarterly) | 0.5107 |
| Free Cash Flow to Equity (Quarterly) | 91.56M |
| Free Cash Flow to Firm (Quarterly) | 120.52M |
| Free Cash Flow Yield | 2.94% |